Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: PI3K and MAPK inhibitors - COSCIENS Biopharma

Next Previous
X
Search
Drug Profile

Research programme: PI3K and MAPK inhibitors - COSCIENS Biopharma

Alternative Names: AEZS-126; AEZS-129; AEZS-129-136; AEZS-131; AEZS-132; AEZS-134; AEZS-136; AEZS-136 PI3K/Erk dual inhibitor - COSCIENS Biopharma; AEZS-140; D-106669; D-87503

Latest Information Update: 08 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AEterna Zentaris Inc
  • Developer COSCIENS Biopharma
  • Class 2 ring heterocyclic compounds; Pyrazines; Pyridines; Pyridones; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Mitogen-activated protein kinase 1 inhibitors; Mitogen-activated protein kinase 3 inhibitors; Ras signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer; Solid tumours

Most Recent Events

  • 06 Aug 2024 AEterna Zentaris Inc is now called COSCIENS Biopharma
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Germany (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in Germany (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top